Pharmacological effectsThe mechanism of action of this product for the treatment of chronic hepatitis B and enhancement of immune system reactivity has not been fully elucidated. Several in vitro experiments have shown that this product promotes the maturation of T-lymphocytes by stimulating mitogen in peripheral blood lymphocytes, increases the levels of interferon α, interferon γ and lymphokines such as interleukin 2 and interleukin 3 secreted by T-cells after activation by antigens or mitogen, and at the same time increases the levels of lymphokine receptors on the surface of T-cells. It may also enhance allogeneic and autologous mixed human lymphocyte responses through activation of CD4 cells. This product may increase the aggregation of pre-NK cells, which can be made more cytotoxic by interferon. In vivo tests have shown that this product can increase the expression level of interleukin 2 receptor in mouse lymphocytes after activation by cutin A, as well as increase the secretion level of interleukin 2. Toxicology studies Genotoxicity: The results of the genotoxicity test of this product are negative. Reproductive toxicity: This product has no significant teratogenic effects on animal fetuses. It is not known whether the use of this product in pregnant women will affect their fertility or cause damage to the fetus. This product should be used by pregnant women only if really needed. Similarly, it is not known whether this product can be secreted through human milk, so caution should be exercised when using this product in lactating women.